1例复发/难治性伯基特淋巴瘤患儿使用格菲妥单抗的药学监护

打开文本图片集

【中图分类号】R97 【文献标识码】A

【Abstract】This article reports the clinical pharmacist's involvement in managing a case of recurrent/refractory Burkitt lymphoma （R/R BL） treated with glofitamab. After the initial infusion，the patient developed cytokine release syndrome （CRS）.Following physician-pharmacist consultation and evaluation， tocilizumab was administered to mitigate cytokine storm and albumin expansion，along with electrolyte replacement， antipyretics，and anti-infective therapy. Subsequent administration of immunological cell-related neurotoxicity syndrome triggered diazepam for seizure control and glucocorticoids， supplemented by blood pressure reduction and oxygen therapy. The pharmacist provided pharmacological recommendations regarding fever， infections，and seizures during treatment， which the physician subsequently adopted.As there are currently no domestic reports on pediatric cases using glofitamab for R/R BL，this case study offers valuable insights for rational drug use in pediatric patients and demonstrates effctive pharmacological monitoring during immunotherapy.

【KeyWords】Relapsed/refractory Burkitt lymphoma; Children; Glofitamab; Adverse drug reaction Pharmaceutical care

伯基特淋巴瘤（Burkittlymphoma，BL）是一种高度侵袭性的B细胞非霍奇金淋巴瘤（B-cell non-Hodgkin lymphoma，B-NHL），好发于儿童及青少年，约占儿童非霍奇金淋巴瘤病例的 30%[1] 。（剩余13012字）